|
|
 |
|
Viewing report
|
|
|
|
GTC Biotherapeutics Inc: Premium Company Profile
Datamonitor, Jan 2008, Pages: 48
GTC Biotherapeutics is engaged in the development, production and commercialization of therapeutic proteins expressed and purified from the milk of transgenic animals such as goats and cattle. ATryn, the companys major product, is a recombinant human antithrombin produced in the milk of transgenic goats.
Scope of this title
- Contains corporate strategy, value chain presence and SWOT Analysis
- Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors
- Includes information on suppliers/ partners, shareholding structure and key employees with biographies
Highlights of this title
GTC develops, produces, and commercializes therapeutic proteins through transgenic animal technology. In addition to ATryn, GTC is working with LFB Biotechnologies to develop recombinant forms of human factor VIIa and a CD20 monoclonal antibody.
Total revenues of the company witnessed decline at a CAGR of 11% during 2002-2006, from $10 million to $6 million. It derives its revenues from collaborative agreements which include non-refundable license fees, funding of research and development, payments based upon the achievement of certain milestones and royalties.
Between 2006 and 2010, the companys revenues are forecasted to increase at a CAGR of 22% from $6 million to $13 million. There will be an absolute growth of +$7 million in the companys total revenues by 2010. The company is expected to receive all of its revenues through collaborative agreements with its partners.
Key reasons to purchase this title
- Access all the important information and analysis on the company in a single report
- Understand companys strengths, weaknesses, opportunities and threats along with business strategy and value chain
- Gain access to companys adjusted five year financial data along with key ratios and market capitalization
|
|
|
|
